Microparticles from Kidney-Derived Mesenchymal Stem Cells Act as Carriers of Proangiogenic Signals and Contribute to Recovery from Acute Kidney Injury

Choi, Hoon Young; Moon, Sung Jin; Ratliff, Brian B.; Ahn, Sun Hee; Jung, Ara; Lee, Mirae; Lee, Seol; Lim, Beom Jin; Kim, Beom Seok; Plotkin, Matthew; Ha, Sung Kyu; Park, Hyeong Cheon

doi:10.1371/journal.pone.0087853

Cited by 92 publications

(90 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 , OSR1 12 , CITED1 7 genes and the transcriptional factors PAX2 13 and WT1 14 . Other 13 markers were reported as being involved in segment specification, such as the Wnt target gene 14…”

Section: Eya1mentioning

confidence: 99%

Therapeutic use of human renal progenitor cells for kidney regeneration

Bussolati

Camussi

2015

Nat Rev Nephrol

View full text Add to dashboard Cite

show abstract

Section: Eya1mentioning

confidence: 99%

Therapeutic use of human renal progenitor cells for kidney regeneration

Bussolati

Camussi

2015

Nat Rev Nephrol

View full text Add to dashboard Cite

show abstract

“…A further source of MVs with renoprotective activity is the kidney mesenchymal stem cells (KMSC). These microparticles were isolated from the supernatants of KMSC cultured in anoxic conditions in serum-deprived media for 24 h; when injected in mice with acute renal ischemia, they significantly improved renal function, favoring endothelial cells proliferation and ameliorating peritubular microvascular rarefaction [51] . …”

mentioning

confidence: 99%

Potential advantages of acute kidney injury management by mesenchymal stem cells

Bianchi¹,

Sala²,

Donadei³

et al. 2014

WJSC

View full text Add to dashboard Cite

Core tip: Mesenchymal stem cells (MSCs) may have an important therapeutic potential in acute kidney injury management. A body of evidence has demonstrated that MSCs act through a paracrine/endocrine secretion of soluble factors and microvesicles. We summarize preclinical studies and ongoing clinical trials that evaluate the role of MSCs in restoring kidney function. We critically explain the current concerns about the use of MSCs and microvesicles that limit their applications in clinical trials. Then, we propose the future directions that could lead to extend MSCs use in humans.Bianchi F, Sala E, Donadei C, Capelli I, La Manna G. reperfusion injury (IRI) is a major cause of AKI, and it is characterized by acute tubular injury and rapid renal dysfunction, generally caused by ischemic or toxic insults [1][2][3] . The kidney undergoing IRI presents an extensive and complex inflammatory/oxidative stress response, that may result in fibroblast proliferation and excessive deposition of extracellular matrix and has been recognized as a major contributor to end-stage kidney disease [4] . Although many efforts have been made to deal with this problem, such as new drugs and modern dialysis techniques, innovative interventions beyond supportive therapy are not available yet [5] ; therefore, a potent therapeutic intervention for ischemia AKI is imperative. In recent years, a promising approach to manage renal IRI is the use of mesenchymal stem cells (MSCs). Their use in treating different kind of diseases as immunological, vascular, cardiac and renal diseases has been extensively explored [6,7] . MSCs can be isolated from various sources, such as bone marrow or adipose tissue, but other organs have their own niches of MSC-like cells, such as the kidney. Besides their broad distribution in the body and an easy isolation, the interest in MSC was originally raised by their capacity to differentiate into other cell types, suggesting that they could be a source of healthy cells to repair/replace injured tissue [8] .There is evidence from both in vitro studies and animal models of AKI that MSCs can promote regenerative responses in the injured kidney, leading to tissue repair and improvement of renal function [9][10][11] . These beneficial effects have been initially ascribed to the trans-differentiation of MSCs into organ specific cells. However, at least in the kidney, this is a very rare event and the kidneyprotective effects of MSCs have been attributed mainly to paracrine mechanisms [12] . This review will focus on the application of cell therapy in AKI, and it will summarize the recent preclinical and clinical results about the use of MSCs in renal IRI (Figure 1). THERAPEUTIC POTENTIAL OF MESENCHYMAL STEM CELLSMesenchymal stem cells are undifferentiated adult stem cells derived from mesodermal embryonic layer that can differentiate into a broad range of different mesenchymal tissues, including cartilage, bone, muscle, stroma, fat, tendon, and other connective tissues [13] . These cells have been originally isolated f...

show abstract

“…In IRI‐induced acute kidney injury (AKI) mouse model, MSC‐EVs protected mouse from AKI and restored kidney function by inhibiting apoptosis and stimulating tubular epithelial cell proliferation (Gatti et al, ; Wang et al, ; Zhang et al, ). Interestingly, these reno‐protective effects were also found in the EVs isolated from kidney resident MSCs (Choi et al, ).…”

Section: Mscs In Regenerative Medicinementioning

confidence: 83%

Mesenchymal Stem Cell (MSC)‐Derived Extracellular Vesicles: Potential Therapeutics as MSC Trophic Mediators in Regenerative Medicine

Yuan

Zhang

Chen

2019

The Anatomical Record

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are pluripotent progenitor cells with the capabilities of self-renewing, differentiating into multiple lineages, and achieving trophic effects during tissue repair. MSCs can secrete extracellular vesicles (EVs) including exosomes and microvesicles, which mediate their trophic effects on other cells. Carrying a variety of intracellular molecules of MSCs including lipids, proteins, RNA (mRNA and noncoding RNA), and DNA, EVs deliver them into other cells to regulate tissue regeneration process. The therapeutic effects of MSC-derived EVs have been observed in a number of animal disease models. In this review, we focus on the current state and future directions of MSC-derived EVs in regenerative medicine.

show abstract

Microparticles from Kidney-Derived Mesenchymal Stem Cells Act as Carriers of Proangiogenic Signals and Contribute to Recovery from Acute Kidney Injury

Cited by 92 publications

References 29 publications

Therapeutic use of human renal progenitor cells for kidney regeneration

Therapeutic use of human renal progenitor cells for kidney regeneration

Potential advantages of acute kidney injury management by mesenchymal stem cells

Mesenchymal Stem Cell (MSC)‐Derived Extracellular Vesicles: Potential Therapeutics as MSC Trophic Mediators in Regenerative Medicine

Contact Info

Product

Resources

About